Evidence map›Paper›PMID 35820540›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2022

Antibody-mediated depletion of programmed death 1-positive (PD-1

Yujia Zhai, Shuyun Dong, Haojia Li, Yue Zhang, Paul Shami, Mingnan Chen

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yujia ZhaiDepartment of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
Shuyun DongDepartment of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA.
Haojia LiDivision of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA.
Yue ZhangDivision of Epidemiology, Department of Internal Medicine, University of Utah, Salt Lake City, UT 84132, USA.
Paul ShamiDivision of Hematology and Hematologic Malignancies, Department of Internal Medicine, and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Mingnan ChenDepartment of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA. Electronic address: mingnan.chen@utah.edu.
University of Utah · USHuntsman Cancer Institute · US

Funding

Targeted depletion of programmed death-1 positive cells, a method that not only stops autoimmune attack but also preserves adaptive immunityR01AI139535 · NIAID · UNIVERSITY OF UTAH · PI CHEN, MINGNAN · 2019 to 2024
$2.7M
NIAID NIH HHS R01 AI139535
6 · The paper itself

Abstract

PD-1 immune checkpoint has been intensively investigated in pathogenesis and treatments for cancer and autoimmune diseases. Cells that express PD-1 (PD-1

Indexed as

Autoimmune DiseasesProgrammed Cell Death 1 ReceptorAnimalsApoptosisImmunoglobulin GMiceReceptors, FcImmunoglobulin GProgrammed Cell Death 1 ReceptorReceptors, FcAntibody-mediated cell phagocytosisAutoimmune diseasescancerComplement-dependent cytotoxicityDepleting antibodyPD-1PD-1(+) cellPD-1-positive cellProgrammed death-1

Identifiers

PMID35820540
PMCPMC10699550
OpenAlexW4285397242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.